Links Between Cognitive Functions and Clinical, Biological and Neuroradiological Outcomes in Adults With Sickle Cell Disease.


Sickle cell disease (SCD) is an inherited blood disorder. Symptoms include acute and chronic complications. Due to progress in SCD care, patients with SCD are living longer than before and we focus more attention in chronic complications. Children with SCD experience worse cognitive functions than healthy children, and fewer is known about cognitive functions in adults. Studies suggest lower cognitive performance in SCD, mostly in executive functions and processing speed, but the biological and anatomical substrates of cognitive decline are not yet well established in SCD. Often times, cognitive impairments and cerebral disorders are not diagnosed and treated in adults with SCD. The main objective of this study is to propose a deep neuropsychological assessment in adults with SCD and cognitive complaints and to highlight links between cognitive functions and clinical, biological and neuroradiological markers. The hypothesis of this study is that cognitive functions are associated with severity of the SCD, with bood abnormalities, with MRI markers and Transcranial Doppler (TCD) markers of cerebrovascular disease. The secondary objective of this study is to validate a brief cognitive assessment tool (BEARNI tool) in adults with SCD. This study is an observational cross-sectional study that will enroll adults with SCD and cognitive complaint.

Full Title of Study: “Cognitive Functions in Adults With Sickle Cell Disease and Cognitive Complaints: Neuropsychological Assessment and Links to Demographic, Clinical, Biological, Neuroradiological Outcomes and Validation of a Cognitive Assessment Tool.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 13, 2024


  • Behavioral: BEARNI Tool
    • BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory. The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available.

Arms, Groups and Cohorts

  • Sickle cell disease patient
    • Adults with sickle cell disease (homozygous SS or heterozygous SC, Sβ0 or Sβ+) with cognitive complaint.

Clinical Trial Outcome Measures

Primary Measures

  • BEARNI questionnaire
    • Time Frame: Day 0
    • Cognitive performance will be evaluated by a large neuropsychological assessment. The cognitive score will be interpreted as raw scores, z-score adjusted for level of education, age, and sex, according to the tests and binarized into two categories (normal versus pathological performances)

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years old – Sickle cell anemia (homozygous SS or heterozygous SC, Sβ0, S/C, Sβ+) – In steady state (without vaso-occlusive crisis or acute chest syndrome at the time of measurements) – Presence of spontaneous cognitive complaint or requested by the physician. – Good command of the French language (native language or not) – No objection to participate in the study – Affiliated patient or beneficiary of social security scheme Exclusion Criteria:

  • Patient not compliant in the management of his disease – Patient participating in another interventional research protocol that may interfere with this protocol (according to investigator's judgment) – Language barrier – Pregnancy or breast feeding – MRI contraindication – Patient under guardianship , curatorship or justice – Inability to express non-opposition

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Antoine GARNIER-CRUSSARD, 04 72 43 21 27,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.